Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Metabolism of properdin in normal subjects and patients with renal disease.
J B Ziegler, … , W Grupe, I H Lepow
J B Ziegler, … , W Grupe, I H Lepow
Published September 1, 1975
Citation Information: J Clin Invest. 1975;56(3):761-767. https://doi.org/10.1172/JCI108147.
View: Text | PDF
Research Article

Metabolism of properdin in normal subjects and patients with renal disease.

  • Text
  • PDF
Abstract

Properdin deposition has been recognized in glomeruli of patients with acute and chronic nephritis and lupus nephritis, and low serum properdin levels have been found in these disorders. These findings suggest that properdin may be involved in the production of glomerular damage and that low properdin levels may be due to hypercatabolism. The study was designed to examine the metabolism of properdin in normal subjects and to look for an abnormality in five patients with systemic lupus erythematosus with renal involvement and in six patients with membranoproliferative glomerulonephritis or dense deposit disease (MPGN). Highly purified human properdin was prepared by elution from zymosan, followed by DEAE-cellulose and carboxymethyl-Sephadex chromatography, and labeled with 125I by the iodine monochloride method. Parameters of metabolism were determined by monitoring plasma and urinary radioactivity at frequent intervals after the intravenous injection of 1-2 muCi of labeled material. The fractional catabolic rate (FCR) of properdin in normal subjects was found to have a very narrow range of 0.78-1.0,% of the plasma pool per hour (mean 0.95%). In systemic lupus erythematosus, the FCR was regularly elevated with a range of 1.21-2.30% (mean 1.70%). In MPGN, FCR was elevated in three patients (1.22, 1.94, and 2.08%) and within or below the normal range in three (0.78, 1.00, and 1.00%). Properdin levels were reduced in two patients who had the highest FCR's noted in the study. Properdin synthetic rates in normals varied from 4.1 to 14.3 mug/kg per h (mean 9.1) and was not found to be reduced in any patient. Properdin catabolism was found to be normal in a patient deficient in the C3b inactivator. These studies show that properdin is hypercatabolized in patients with renal disease and that decreased properdin levels when they occur in these patients can be entirely explained on the basis of this hypercatabolism.

Authors

J B Ziegler, F S Rosen, C A Alper, W Grupe, I H Lepow

×

Total citations by year

Year: 2020 2018 2016 2013 1991 1990 1984 1983 1981 1980 1979 1977 1976 Total
Citations: 2 1 1 1 2 1 3 2 2 1 2 2 3 23
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (23)

Title and authors Publication Year
Mathematical Modelling of Alternative Pathway of Complement System
S Bakshi, F Cunningham, EM Nichols, M Biedzka-Sarek, J Neisen, S Petit-Frere, C Bessant, L Bansal, LA Peletier, S Zamuner, PH van der Graaf
Bulletin of Mathematical Biology 2020
Clinical and functional consequences of anti‐properdin autoantibodies in patients with lupus nephritis
M Radanova, G Mihaylova, D Ivanova, M Daugan, V Lazarov, L Roumenina, V Vasilev
Clinical & Experimental Immunology 2020
Role of properdin in complement-mediated kidney diseases
MF van Essen, JM Ruben, AP de Vries, C van Kooten
Nephrology Dialysis Transplantation 2018
Properdin: a tightly regulated critical inflammatory modulator
AZ Blatt, S Pathan, VP Ferreira
Immunological Reviews 2016
Properdin and factor h: opposing players on the alternative complement pathway "see-saw"
L Kouser, M Abdul-Aziz, A Nayak, CM Stover, RB Sim, U Kishore
Frontiers in immunology 2013
INHERITED DEFICIENCIES OF COMPLEMENT PROTEINS : with special reference to congenital deficiency of the regulatory protein factor I
JE RASMUSSEN
APMIS 1991
INHERITED DEFICIENCIES OF COMPLEMENT PROTEINS: with special reference to congenital deficiency of the regulatory protein factor I
JE RASMUSSEN
APMIS 1991
Advances in Human Genetics
H Harris, K Hirschhorn
1990
Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum
JT Mayes, RD Schreiber, NR Cooper
Journal of Clinical Investigation 1984
Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus
D Adu, DG Williams
Clinical & Experimental Immunology 1984
Pathophysiology of Plasma Protein Metabolism
G Mariani
1984
Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema
M Quastel, R Harrison, M Cicardi, CA Alper, FS Rosen
Journal of Clinical Investigation 1983
Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus
MR Daha, HM Hazevoet, J Hermans, LA van Es, A Cats
Clinical & Experimental Immunology 1983
Molecular aspects of complement activation
K Whaley, A Ferguson
Molecular Aspects of Medicine 1981
Immunological Aspects of Rheumatology
WC Dick
1981
Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins
MT Aguado, LH Perrin, R Ramirez, PA Miescher, PH Lambert
Clinical & Experimental Immunology 1980
Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus
K Whaley, PH Schur, S Ruddy
Clinical & Experimental Immunology 1979
Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis
K Whaley, D Ward, S Ruddy
Clinical & Experimental Immunology 1979
Severe systemic lupus erythematosus with nephritis in a boy with deficiency of the fourth component of complement
JG Schaller, BG Gilliland, HD Ochs, JP Leddy, LC Agodoa, SI Rosenfeld
Arthritis & Rheumatism 1977
Pathways of complement activation in chronic discoid lupus
MA Schrager, NF Rothfield
Arthritis & Rheumatism 1977
Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus
MA Schrager, NF Rothfield
Journal of Clinical Investigation 1976
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase
K Whaley, PH Schur, S Ruddy
Journal of Clinical Investigation 1976
Activation of the alternative complement pathway in systemic lupus erythematosus
MR Wilson, CM Arroyave, RM Nakamura, JH Vaughan, EM Tan
Clinical & Experimental Immunology 1976

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts